The Tumor Suppressor PP2A Aβ Regulates the RalA GTPase  by Sablina, Anna A. et al.
The Tumor Suppressor PP2A Ab
Regulates the RalA GTPase
Anna A. Sablina,1,6 Wen Chen,1,4,6 Jason D. Arroyo,1,2,6 Laura Corral,5 Melissa Hector,1 Sara E. Bulmer,1
James A. DeCaprio,1 and William C. Hahn1,2,3,*
1Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women’s Hospital
and Harvard Medical School, Boston, MA 02115, USA
2Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
3Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
4Department of Toxicology, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China
5DF/HCC Monoclonal Antibody Core, Dana-Farber Cancer Institute, Boston, MA 02215, USA
6These authors contributed equally to this work.
*Correspondence: william_hahn@dfci.harvard.edu
DOI 10.1016/j.cell.2007.03.047SUMMARY
The serine-threonine protein phosphatase 2A
(PP2A) is a heterotrimeric enzyme family that
regulates numerous signaling pathways. Bial-
lelic mutations of the structural PP2A Ab sub-
unit occur in several types of human tumors;
however, the functional consequences of these
cancer-associated PP2A Ab mutations in cell
transformation remain undefined. Here we
show that suppression of PP2A Ab expression
permits immortalized human cells to achieve
a tumorigenic state. Cancer-associated Ab
mutants fail to reverse tumorigenic phenotype
induced by PP2A Ab suppression, indicating
that these mutants function as null alleles.
Wild-type PP2A Ab but not cancer-derived Ab
mutants form a complex with the small GTPase
RalA. PP2A Ab-containing complexes dephos-
phorylate RalA at Ser183 and Ser194, inact-
ivating RalA and abolishing its transforming
function. These observations identify PP2A Ab
as a tumor suppressor gene that transforms
immortalized human cells by regulating the
function of RalA.
INTRODUCTION
Reversible protein phosphorylation plays a critical role in
cell physiology, and dysregulation of the mechanisms
that control specific phosphorylation events contributes
directly to disease. Indeed, inappropriate kinase activa-
tion plays a causal role in most cancers, and we now
understand the role of several kinase oncogenes in pro-
gramming the malignant phenotype (Broach and Levine,
1997; Hanahan and Weinberg, 2000). In contrast, much
less is known concerning the function of phosphatases
in cancer development.Studying transformation in human cell culture models
has helped elucidate pathways related to spontaneous
cancer development (Hahn and Weinberg, 2002). We
previously demonstrated that ectopic expression of the
telomerase catalytic subunit (hTERT), the SV40 Early
Region (SV40 ER), and an oncogenic allele of H-RAS con-
fers a tumorigenic phenotype to several types of normal
human cells (Zhao et al., 2004). Subsequent work has
now defined combinations of cancer-associated muta-
tions that suffice to transform human cells (Boehm et al.,
2005; Drayton et al., 2003; Seger et al., 2002). Indeed,
the SV40 ER encodes two oncoproteins, the SV40 large
T (LT) and small t (ST) antigens. LT binds the retinoblas-
toma and p53 proteins and in turn inactivates these two
tumor suppressor pathways (Ali and DeCaprio, 2001),
activities central to its role in human cell transformation
(Hahn et al., 2002; Voorhoeve and Agami, 2003).
ST binds the serine-threonine protein phosphatase 2A
(PP2A), and this interaction is essential for ST to transform
cells (Hahn et al., 2002; Sugano et al., 1982; Yu et al.,
2001). The viral oncoproteins SV40 ST, the small and mid-
dle T antigens of polyoma virus, and the adenoviral protein
E4orf4 all bind PP2A [reviewed in (Schonthal, 2001)], sug-
gesting that like other targets of viral oncoproteins, PP2A
plays an important role in tumor suppression (Pallas et al.,
1990; Hahn et al., 2002). The involvement of PP2A in trans-
formation is also supported by the observation that the
PP2A inhibitor, okadaic acid (OA), is a potent tumor pro-
moter (Suganuma et al., 1988).
PP2A comprises a family of ubiquitously expressed
serine-threonine phosphatases implicated in regulation
of many signaling pathways. PP2A holoenzymes are com-
posed of three subunits, a catalytic C subunit, a structural
A subunit, and a regulatory B subunit. Each of these
subunits is encoded by several distinct genes, which are
assembled to create numerous ABC holoenzymes [re-
viewed in (Janssens and Goris, 2001)]. The large number
of different PP2A heterotrimers suggests that specific
regulatory subunits mediate particular physiological
functions.Cell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc. 969
Suppressing the expression of the PP2A B56g regula-
tory subunit or partially depleting the structural Aa subunit
cooperates with LT, hTERT and H-RAS to convert human
cells to tumorigenicity (Chen et al., 2005, 2004). Although
mutations of PP2A Aa occur at low frequency in human
tumors (Calin et al., 2000), mutations of the second
PP2A A subunit, Ab, are more common (Calin et al.,
2000; Ruediger et al., 2001a; Takagi et al., 2000; Tamaki
et al., 2004; Wang et al., 1998). Specifically, somatic
mutations of Ab, including point mutations, deletions,
frameshifts, and splicing abnormalities, have been found
in 8%–15% of colon cancers, 15% of lung cancers, 13%
of breast cancers, and 6% of tumor cell lines (Calin
et al., 2000; Ruediger et al., 2001a; Takagi et al., 2000;
Tamaki et al., 2004; Wang et al., 1998). These cancer-
associated PP2A Ab mutants are defective in binding to
B and/or C subunits in vitro (Ruediger et al., 2001a). In
addition to mutations, the PP2A Ab gene is located at
11q23, a chromosomal region frequently deleted in human
cancers (Baysal et al., 2001). Moreover, reduced expres-
sion of the PP2A Ab subunit has been found in 16 of 32
cancer cell lines derived from human lung, colon, breast,
and cervical carcinomas (Zhou et al., 2003). While these
observations implicate PP2A Ab as a tumor suppressor
gene, the mechanism by which Ab loss of function contrib-
utes to tumor development remains undefined. Here we
assess the impact of Ab dysfunction in human cell trans-
formation and identify RalA as an interacting effector
protein regulated by PP2A Ab complexes.
RESULTS
Suppression of PP2A Ab Expression Transforms
Human Cells
To assess the role of PP2A Ab structural subunit in human
cell transformation, we suppressed Ab expression in im-
mortal, nontumorigenic HEK cells expressing LT, hTERT,
and H-RAS (HEK TER) cells using a short hairpin RNA
(shRNA) specific for Ab (shAb). Introduction of shAb into
HEK TER cells overexpressing FLAG-tagged PP2A Ab
led to suppression of the ectopically expressed Ab
(Figure 1A). We then generated HEK TER cell lines that
stably harbored either shAb (HEK TER-shAb) or a control
shRNA targeting GFP (shGFP) (HEK TER-shGFP). Expres-
sion of shAb in HEK TER cells reduced Ab mRNA levels by
78 ± 6% compared to those found in control cells
(Figure 1B).
In parallel, we generated a HEK TER cell line expressing
shRNA targeting the other structural PP2A A subunit (Aa)
(Figure 1C). Suppression of the PP2A Aa subunit resulted
in a substantial reduction of the levels of the PP2A B55a
and B563 regulatory subunits and the catalytic Ca subunit
(Figure 1C, left panels). These observations corroborate
prior work that demonstrated that the PP2A regulatory
and catalytic subunits exhibit limited stability when not
bound to a structural PP2A A subunit (Silverstein et al.,
2002). In contrast, suppressing PP2A Ab expression failed
to alter the levels of these regulatory and catalytic PP2A970 Cell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc.subunits (Figure 1C, right panels). In consonance with
these findings, we observed that PP2A-attributable phos-
phatase activity was decreased by 80 ± 6% or 13 ± 3% in
cells expressing shAa or shAb, respectively, compared to
control shGFP cells (Figure 1D). These findings confirm
previous observations (Hemmings et al., 1990; Zhou
et al., 2003) that concluded that PP2A complexes contain-
ing Ab represent a small fraction of the total PP2A
complexes.
We next examined the effects of suppressing either
PP2A Aa or Ab on proliferation, anchorage-independent
(AI) growth and tumor formation. Consistent with our prior
work (Chen et al., 2005), we found that HEK TER cells
expressing very low levels of Aa proliferated poorly and
failed to grow in an AI manner or to form tumors (Figures
1E, 1F, and S1D in the Supplemental Data available with
this article online). In contrast, suppression of the PP2A
Ab subunit induced a small increase in the rate of prolifer-
ation (Figure 1E), conferred the ability to grow in an AI
manner, and permitted these cells to form tumors (Figures
1F and S1A).
To exclude the possibility that these observations
were due to off-target effects of RNAi, we used a second
shRNA that targets a different region of the PP2A Ab
mRNA (shAb-2). This second shRNA also efficiently sup-
pressed Ab expression in HEK TER cells and permitted
these cells to grow in an AI manner (Figures S1B and
S1C). Overexpression of a PP2A Ab allele resistant to sup-
pression by shAb (Figure S1D) reversed the observed
transformed phenotype (Figures 1G and 2B). Moreover,
we found that suppression of Ab expression in immortal,
human small airway epithelial cells expressing hTERT,
LT, and H-RAS (AATER cells) (Lundberg et al., 2002)
also permitted AI growth (Figure 1G), indicating that the
observed effects of suppressing Ab are not restricted to
a particular cell type. Together, these results suggest
that loss of PP2A Ab expression contributes directly to
cell transformation.
Cancer-Associated PP2A Ab Mutants
Are Functionally Defective
Mutations in PP2A Ab are found in lung, breast and colon
cancers and include missense mutations involving P65S,
L101P, V448A, V545A, G8R, K343E and L101P/V448A
(Wang et al., 1998). In addition, one PP2A Ab mutation
involves the deletion of exon 9, resulting in an in-frame
deletion of 45 amino acids (DE344–E388). To study the
function of these cancer-associated mutants, we gener-
ated FLAG-epitope tagged versions of wild-type (WT)
PP2A Ab or cancer-derived Ab mutants. We overex-
pressed these Ab alleles in HEK TER cells and determined
whether such Ab mutants formed functional PP2A com-
plexes. In Ab immune complexes, we found that the WT
PP2A Ab subunit formed heterotrimers with the catalytic
Ca and each of the regulatory B subunits tested (Figures
2A, S2A, and S2B). In contrast, each of the cancer-derived
Ab mutants showed clear defects in their ability to form
productive PP2A complexes (Figure 2A, lower panel,
Figure 1. Suppression of PP2A Ab Expression Induces Transformation
(A) Suppression of FLAG-tagged PP2A Ab in 293T cells by an Ab-specific shRNA as assessed by immunoblotting.
(B) Suppression of endogenous PP2A Ab expression in HEK TER as assessed by quantitative RT-PCR.
(C) Expression of PP2A subunits (total A, B55a, B563, and Ca subunits) in cells in which Aa or Ab was suppressed by the indicated shRNA.
(D) PP2A-specific phosphatase activity in HEK TER cells expressing Aa- or Ab-specific shRNAs.
(E) Proliferation of HEK TER cells expressing shGFP, shAa, shAb, or ST.
(F) AI growth and tumorigenicity of the cell lines indicated in E. Tumors are reported as number of tumors formed per number of injection sites.
(G) AI growth of AATER cells lacking Ab expression. RA Ab is an allele of Ab resistant to shAb.
For (B), (D), (E), (F), and (G), data shown as mean ± SD for three independent experiments.and Figures S2A–S2C), corroborating a prior report (Rue-
diger et al., 2001a).
We next determined whether these Abmutants retained
phosphatase activity by measuring PP2A Ab-attributable
phosphatase activity in Ab immune complexes isolated
from HEK TER cells expressing WT or mutant PP2A forms
of Ab (Figure 2A). We found that the phosphatase activity
associated with mutant Ab (P65S, V545A, G8R, K343E or
D504G) immune complexes was reduced by 48 ± 5%,
70 ± 7%, 68 ± 9%, 52 ± 4%, or 71 ± 9% respectively, com-
pared to the activity levels found with the WT Ab subunit.
We failed to detect any Ab-attributable phosphatase
activity in cells expressing the Ab mutants L101P/V448A,
DE344-E388, L101P, and V448A (Figure 2A). Thus, we
concluded that cancer-associated mutations of PP2A Ab
mutants fail to form the full compliment of PP2A com-
plexes and demonstrate impaired mutant-specific phos-
phatase activity.
Loss-of-Function of Both Ab Alleles Is Necessary
to Transform Human Cells
To determine whether Ab mutants exhibit gain of function
properties, we measured the total PP2A-specific phos-
phatase activity in cells overexpressing WT Ab or Abmutants. Introduction of WT Ab or the P65S or G8R Ab
mutants resulted in a slight increase in total phosphatase
activity, while no changes in overall activity were found in
cells expressing other Abmutants (Figure S3). Thus, PP2A
Ab mutants did not disrupt endogenous phosphatase
activity by acting as dominantly acting negative alleles.
Moreover, introduction of the WT allele of PP2A Ab or
any of the mutant PP2A Ab alleles into immortalized but
nontumorigenic HEK TER cells failed to transform these
cells, confirming that these mutations fail to act as domi-
nant oncogenes (data not shown).
In consonance with these observations, Ab mutant
alleles are usually accompanied by the deletion of the
second allele in human tumor samples (Tamaki et al.,
2004; Wang et al., 1998). To mimic this situation, we gen-
erated WT and mutant alleles of Ab (RAb) that are resistant
to targeting by shAb and expressed them in HEK TER-
shAb cells (Figures S1D and 2B, lower panel). We found
that expression of the WT PP2A Ab (RAb) in tumorigenic
HEK TER-shAb cells decreased cell proliferation by
36% (Figure S4A). In contrast, expression of each of the
Ab mutants failed to alter substantially the proliferation
rate of shAb cells (Figure S4A). Introduction of RAb in
HEK TER-shAb or AATER-shAb cells also significantlyCell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc. 971
Figure 2. Analysis of Cancer-Derived PP2A Ab Mutants
(A) Binding of Ab mutants to the PP2A Ca catalytic subunit and phosphatase activity of PP2A-specific complexes containing Ab mutants. FLAG-
tagged WT Ab and Ab mutants were overexpressed HEK TER cells, FLAG immune complexes were isolated, and immunoblotting was performed
using antibodies against FLAG or PP2A Ca subunits (lower panel). Ab-specific phosphatase activity was determined in the immune complexes by
measuring the release of PO4
3- from the substrate phosphopeptide [RRA(pT)VA].
(B) Effect of expressing PP2A Ab mutations on AI growth and tumor formation. FLAG-tagged shAb-resistant forms of Ab were overexpressed in HEK
TER-shAb and expression confirmed by immunoblotting (anti-FLAG M2 antibody, bottom). Tumors are reported as the number of tumors formed per
the number of injection sites.
(C) Overexpression of WT Ab in AATER cells and lung carcinoma cells. Ab expression in AATER cells and lung cancer cell lines (H1437, H2009, H1450
and H838) was confirmed by immunoblotting using a pan-PP2A A subunit-specific antibody (upper bands to correspond Ab and lower bands
correspond to Aa).
(D) Effect of WT Ab overexpression on proliferation rates of cell lines indicated in C. PD = population doubling as previously defined (Chen et al., 2005).
(E) AI growth of cell lines indicated in C. *p < 0.0008 and **p < 0.0019 as determined using the Student’s t test.
(F) Kinetics of tumor growth of H2009 and H1450 cells expressing a control vector or WT Ab. 6 xenografts for each cell line were studied.
*p < 0.83 and **p < 0.039 as determined by ANOVA. V, control vector. Mean ±SD for three independent experiments are shown in bar and line graphs.972 Cell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc.
Table 1. Effects of Wild-Type Ab Expression on Cell Cycle and Apoptosis
Cell Line Doubling Time (hr) G0/G1 S (%) G2/M Apoptotic Cells (%)
AALER-V 55 ± 9 55.4 ± 9.3 22.5 ± 4.3 22.1 ± 3.6 4.5 ± 0.5
AALER-Ab 58 ± 8 58.3 ± 7.7 20.4 ± 3.1 21.3 ± 2.3 4.6 ± 0.3
H1437-V 21 ± 3 33.5 ± 5.3 42.6 ± 5.6 23.9 ± 2.5 2.3 ± 0.5
H1437-Ab 41 ± 5 35.5 ± 4.4 45.9 ± 4.2 18.8 ± 2.4 3.5 ± 0.8
H2009-V 24 ± 3 51.3 ± 5.7 28.5 ± 2.7 20.2 ± 4.9 5.3 ± 0.6
H2009-Ab 25 ± 1 53.5 ± 6.8 27.7 ± 1.8 19.9 ± 2.9 4.9 ± 0.5
H1450-V 20 ± 4 40.3 ± 5.5 33.5 ± 2.7 26.2 ± 4.7 5.3 ± 0.6
H1450-Ab 53 ± 6 73.5 ± 9.6** 8.7 ± 1.8** 17.8 ± 2.9 4.9 ± 0.5
H838-V 22 ± 3 46.7 ± 6.6 36.4 ± 5.2 16.9 ± 2.6 3.8 ± 0.4
H838-Ab 41 ± 6 75.3 ± 6.8** 8.9 ± 1.2** 15.8 ± 2.3 4.1 ± 0.5
Proliferation rate of lung carcinoma cell lines expressing a control vector (V) or wild-type Ab was analyzed as described in Supple-
mental Experimental Procedures. Cell-cycle distribution of these cells was determined by analysis of BrdU/PI stained cells.
Apoptosis level was measured by analysis of double Annexin V/PI-stained cells. Data shown as mean ± SD. **p < 0.01 was deter-
mined using the Student’s t test.suppressed AI growth (62% ± 8% and 67% ± 9%, respec-
tively) and reduced the number of tumors formed,
whereas introduction of other Ab mutants showed no
inhibitory effects on the transformed phenotype (Figures
1G, 2B, and S4B). These observations confirmed that
each of cancer-associated PP2A Abmutants is a function-
ally null allele and that loss-of-function of both Ab alleles is
necessary to induce a fully transformed phenotype.
Restoration of Ab Function in Lung Carcinoma Cells
Reverses the Tumorigenic Phenotype
To investigate the role of PP2A Ab mutations in patient-
derived cancer cell lines, we determined the effects of
restoring PP2A Ab function in lung cancer cell lines that
harbor PP2A Ab mutations. The H1450 and H838 lung
cancer cell lines harbor PP2A Ab subunit mutations
(Wang et al., 1998). The H1450 cell line carries one Ab
allele containing an in-frame deletion of residues 717-
1583 and a second allele with point mutation D504G, while
H838 harbors only one mutant Ab allele (G8R). To examine
whether expression of the Ab subunit reverses the tumor-
igenic phenotype, we introduced the WT Ab allele into
these lung cancer cell lines harboring mutant PP2A Ab
(Figure 2C). As control, we used the primary AATER cells
and two lung carcinoma cell lines - H1437 that harbors
two WT Ab alleles and H2009 that has one WT Ab allele
and a G90D Ab allele. When overexpressed, the Ab
G90D allele behaved in a manner indistinguishable from
WT Ab with regard to forming active PP2A complexes
and suppressing AI growth (data not shown).
Expression of WT Ab in the H1450 and H838 cell lines
suppressed their doubling rate by 68% ± 8% and 58% ±
9%, respectively (Figures 2C and 2D and Table 1) and
reduced the number of AI colonies formed by these cell
lines by 77 ± 8% and 42 ± 5%, respectively (Figure 2E).Moreover, expression of WT Ab into H1450 significantly
suppressed tumor growth (Figure 2F). In contrast, intro-
duction of WT Ab into the H1437, H2009 or AATER cell
lines, each of which carries a WT Ab allele, failed to inhibit
cell proliferation, AI growth or tumor growth, suggesting
that the decreased cell proliferation and AI growth ob-
served in H1450 and H838 cells was not an artifact induced
by overexpression of Ab (Figures 2C–2F and Table 1).
Cell cycle analysis by double 5-bromo,30-deoxyuridine/
propidium iodide (BrdU/PI) staining showed that the intro-
duction of WT Ab into H838 and H1450 cells increased the
percentage of cells present in the G1 phase of the cell
cycle (Table 1). In contrast, expression of WT Ab failed
to affect the cell cycle distribution of AATER, H1437 and
H2009 cells. In all of these cells, we did not detect any
evidence of increased numbers of apoptotic cells after
overexpression of WT Ab (Table 1), suggesting that the
decreased proliferative rate induced by WT Ab in lung
carcinoma cell lines harboring mutant Ab was due to the
lengthening of cell cycle rather than apoptosis.
Suppression of PP2A Aa or Ab Induces
Transformation by Distinctive Mechanisms
We previously reported that partial suppression of PP2A
Aa imparts a tumorigenic phenotype (Figure 3A) by selec-
tively eliminating PP2A B56g containing complexes (Chen
et al., 2004). Although the two distinct PP2A A isoforms,
Aa and Ab, share 86% sequence identity (Hendrix et al.,
1993), it remained unclear whether these isoforms share
overlapping functions. To determine if Aa and Ab were
interchangeable, we overexpressed Aa in HEK TER cells
in which we suppressed Ab expression (HEK TER-shAb).
Overexpression of PP2A Aa in these cells failed to revert
the transformed phenotype induced by Ab suppression,
indicating that the Aa isoform does not functionallyCell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc. 973
Figure 3. Mechanisms of Aa and Ab Tu-
mor Suppression
(A) AI growth and tumor formation of HEK TER
cells expressing shGFP, shAb, shAa (shAa and
LowAa cell lines refer to cells that exhibit 90%
and 50% suppression of Aa expression, re-
spectively), or ST. shAb-resistant WT Ab and
Aa were overexpressed in HEK TER cells lack-
ing Ab expression. The number of AI colonies
formed is presented as mean ± SD for three in-
dependent experiments. Tumors are reported
as the number of tumors formed per number
of injection sites.
(B) Interaction between ST and PP2A structural
subunits. GST-tagged ST was mixed with 293T
cell lysates overexpressing a control vector
(Vector), FLAG-tagged Aa or FLAG-tagged
Ab. The ST-containing complexes were iso-
lated with glutathione-agarose followed by im-
munoblotting using antibodies specific to ST or
the FLAG epitope.
(C) Large-scale immunoprecipitation of FLAG-
tagged Aa or FLAG-tagged Ab overexpressed
in 293T cells using anti-Flag (M2) agarose. Pro-
teins in these respective immune complexes
were separated by SDS-PAGE and stained
with Coomassie Blue. Mass spectrometry
was performed to identify interacting proteins.
(D) Immunoprecipitation of FLAG-tagged Aa or
FLAG-tagged Ab expressed in 293T cells fol-
lowed by immunoblotting using FLAG or RalA
specific antibodies. We note that a small
amount of nonspecific binding of RalA to anti-
FLAG (M2) agarose was found; however, signif-
icantly larger amounts of RalA were found in
complex with FLAG-tagged Ab. E, Reciprocal
immunoprecipitations of FLAG-tagged Ab and
HA-tagged RalA. FLAG-tagged Ab and HA-
tagged RalA were expressed in 293T cells
and immune complexes isolated with anti-
FLAG (M2)- or anti-HA (H7)- agarose respec-
tively. Immunoblotting was performed with
antibodies specific for FLAG, Ca or RalA. F,
Interaction between RalA and cancer-derived
Ab mutants. Anti-FLAG-epitope tag immuno-
precipitation from HEK TER cells expressing
WT PP2A Ab or Ab mutants followed by immu-
noblotting with antibodies specific for FLAG or
RalA.substitute for loss of Ab expression (Figure 3A). Consistent
with these observations, we confirmed that only the PP2A
Aa isoform forms complexes with ST (Zhou et al., 2003)
(Figures 3B and S5). These observations indicate that
suppression of Ab induces transformation by a mechanism
distinct from that caused by partial depletion of PP2A Aa
or by expression of ST.
The Small GTPase RalA Interacts with PP2A Ab
To study the mechanism by which PP2A Ab suppression
contributes to transformation, we purified PP2A Aa and
Ab complexes to identify proteins that bind uniquely to
Ab. Specifically, we overexpressed FLAG-epitope tagged
forms of Aa and Ab in 293T cells, isolated the immune974 Cell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc.complexes formed with these proteins (Figure 3C) and
identified proteins that associate with the Aa and Ab
subunits by mass spectrometry (Figure S6). We found
that the PP2A catalytic Ca and several regulatory B
subunits associated with both the Aa- and Ab-specific
complexes, confirming that these conditions permitted
the isolation of functional heterotrimers (Figures 3C and
S6A). Although most proteins identified by this approach
interacted with both Aa and Ab, we found a small number
of proteins that bound only to PP2A Ab. When we attemp-
ted to verify these putative Ab interacting proteins, we
found that the small GTPase protein RalA was the only
protein that specifically formed complexes with Ab
subunit (Figures 3D and S6B).
RalA has been implicated in the regulation of exocyto-
sis, transcription, secretion, cell transformation and tumor
progression [reviewed in (Feig, 2003; Feinstein, 2005)].
When we overexpressed HA-tagged-RalA and FLAG-
tagged Ab in 293T cells, we found that immune complexes
isolated using either HA- or FLAG-specific antibodies
contained both RalA and Ab (Figure 3E). We also found
that endogenous RalA interacts with FLAG-tagged Ab in
293T cells (Figure 3D) and that both RalA and Ab were
found in membrane fraction of HEK TER-Ab cells
(Figure S7A). In contrast, PP2A Aa failed to form com-
plexes with RalA (Figures 3D and 3E), confirming that
RalA binds specifically PP2A Ab-containing complexes.
We note that RalA-Ab complexes were comprised of
16 ± 5% of the total RalA and 9 ± 2% of the total Ab pro-
teins (Figure S7B). These observations indicate that the
interaction between the PP2A Ab complex and RalA
involves a small fraction of the total PP2A Ab complexes
and RalA and suggests that these interactions are likely
short-lived as would be expected for interactions between
phosphatases and their substrates.
We then determined whether cancer-associated Ab
mutants form complexes with RalA by purifying PP2A Ab
immune complexes from HEK TER cells expressing WT
Ab or cancer-associated Ab mutants (G8R, V454A, and
V448A) representing each of the categories defined in
Figure S2C. WT Ab but not Ab point mutants bound
endogenous RalA (Figure 3F). This observation makes it
unlikely that interaction between WT Ab and RalA is non-
specific and suggests that loss of Ab function also impairs
RalA complex formation.
RalA Is Necessary for Transformation Induced
by PP2A Ab Suppression
To assess whether RalA expression was required for cell
transformation induced by loss of Ab expression, we sup-
pressed RalA expression using two different RalA-specific
shRNAs (shRalA-1 and shRalA-2) (Figure 4A, upper panel).
Immunoblotting with a RalA-specific antibody revealed
that both shRalA-1 and shRalA-2 efficiently suppressed
RalA expression. Suppression of RalA inhibited the prolif-
eration of HEK TER cells expressing shGFP (Figure 4A). In
contrast, suppression of RalA failed to affect the prolifera-
tion rate of the HEK TER-shAb, HEK TER-LowAa, and HEK
TER-ST cell lines. These findings are consistent with prior
observations that showed that RalA is not limiting for
serum-dependent proliferation of tumorigenic cells under
standard culture conditions (Chien and White, 2003).
To examine the contribution of endogenous RalA to
oncogenic transformation, we then tested the conse-
quences of suppressing RalA expression on AI growth.
Depletion of RalA inhibited the ability of HEK TER cells
expressing shAb to form AI colonies by 94% ± 5%
(Figure 4B). In contrast, suppression of RalA in HEK TER
cells expressing ST or in which Aa expression was
decreased by 50% (LowAa) only partially inhibited the
ability of these cells to form AI colonies (37% ± 6% and
61% ± 6%, respectively) (Figure 4B), consistent with priorobservations that showed that oncogenic alleles ofH-RAS
also activate RalGEFs (Lim et al., 2005). These findings
indicate that RalA expression is necessary for the trans-
formed phenotype induced by suppression of Ab.
PP2A Ab Negatively Regulates RalA Activity
To determine whether the interaction of Ab with RalA
perturbs RalA function, we examined RalA activity in
HEK TER cells in which Ab expression was suppressed.
RalA activity was analyzed by determining the amount of
GTP-bound, and therefore active, RalA bound to recombi-
nant Ral-BP1 protein. We found a 4.5-fold increase in
GTP-bound RalA levels in cells lacking Ab compared to
control cells expressing shGFP (Figure 4C). Expression
of ST or partial suppression of Aa had no effect on the
steady state amount of GTP-bound RalA (Figure 4C), con-
sistent with our prior observations that suggested that Ab
induces transformation by a mechanism distinct from that
caused by partial inhibition of Aa or ST overexpression.
In contrast, introduction of exogenous PP2A Ab
inhibited RalA activity in both HEK TER and HEK TER-
shAb cells as measured by decreased levels of GTP-
bound RalA (Figure 4D). To test whether cancer-derived
Ab mutants affected RalA activity, we overexpressed the
shRNA-resistant G8R Ab mutant in HEK TER cells lacking
Ab expression. We found that the G8R Ab mutant that
cannot form complexes with RalA (Figure 3F) also failed
to affect RalA activity (Figure 4D). Consistent with these
findings, the H838 lung cancer cell line that harbors a
single mutant Ab allele exhibited approximately 4-fold
higher levels of RalA activity compared to the H2009
carcinoma cell line that harbors WT Ab (Figure 4D). Over-
expression of WT Ab in both H838 and H2009 cell lines
decreased the amount of GTP-bound RalA identified
using this Ral-BP1 binding assay. Moreover, introduction
of WT PP2A Ab into H838 cells decreased the amount of
activated RalA to the level found in H2009 cells
(Figure 4D). Together, these experiments indicate that
the interaction of Ab with RalA inhibits RalA activity.
PP2A Ab Dephosphorylates RalA
We next determined whether PP2A Ab complexes
dephosphorylate RalA. Using a phospho-serine specific
antibody, we found the accumulation of a serine-
phosphorylated form of RalA in cell lines in which Ab
expression was suppressed (Figure 5A). This observation
suggested that RalA was a direct substrate for Ab PP2A
complexes.
A prior report indicated that RalA can be phosphory-
lated by Aurora A kinase at Ser194 (Wu et al., 2005). To
identify other potential RalA phosphorylation site(s), we
isolated RalA from HEK TER-shAb cells and performed
a mass spectrometric analysis. Although we obtained
highly redundant coverage of most of the RalA protein,
peptides corresponding to the carboxyl-terminal portion
of the protein were underrepresented. This portion of
RalA is highly basic and contains a prenylation site. Of
the portion of RalA that we were able to assess, we foundCell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc. 975
Figure 4. Interplay between RalA and PP2A Ab in Cell Transformation
(A) Proliferation of HEK TER cells expressing a control vector (V), ST, LowAa (50% Aa suppression), or shAb and shRalA or a control shRNA (shGFP).
Immunoblotting with RalA-specific antibodies to assess RalA expression (top). The proliferation data is presented as mean ±SD for three independent
experiments.
(B) AI growth of cell lines described in (A). HEK-TERV cells failed to grow in soft agar. Number of AI colonies formed is presented as mean ± SD for
three independent experiments.
(C and D) Effect of Ab expression on RalA activity. RalA activity was determined by RalA-BP1 binding assay. Amount of GTP-bound RalA was
detected in HEK TER expressing shGFP, SV40 ST, LowAa, shAb or overexpressing WT Aa or Ab (C), RalA activity in HEK TER-shAb cells expressing
a control vector or shAb-resistant forms of WT Ab or G8R Ab mutant and lung carcinoma H2009 and H838 cells expressing control vector (Vector) or
WT Ab.evidence of RalA phosphorylation at Ser11 and Ser183
(data not shown) but no other serine or threonine residues.
To determine whether any of these serine residues were
the target of Ab-containing PP2A complexes, we replaced
each of these three serine residues with alanine and gen-
erated HA-tagged S11A, S183A and S194A RalA mutants.
We co-expressed these RalA alanine substitution mutants
and FLAG-tagged Ab in 293T cells and determined
whether these RalA mutants retained the ability to bind
Ab (Figure 5B). We found that Ab bound to both WT
RalA and the S11A RalA mutant. In contrast, the S183A
and S194A RalA mutants showed diminished ability to
form complexes with Ab (Figure 5B). These observations
suggested that PP2A Ab binds to and dephosphorylates
RalA at Ser183 and Ser194.
To confirm these observations, we created antibodies
that recognize RalA phosphorylated at Ser183/Ser194
by immunizing mice with two KLH-conjugated phospho-976 Cell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc.peptides (phospho-Ser183 and phospho-Ser194). We
found that the sera from one of these immunized mice
and several hybridoma supernatants derived from this
immunized mouse contained antibodies specific for RalA
phosphorylated at Ser183 and Ser194 (Figures 5C, and
S8A–S8C). Specifically, sera from one of the immunized
mice harbored antibodies that recognized both phosphor-
ylated and nonphosphorylated forms of RalA. One hybrid-
oma line derived from this mouse (XL13), bound only
phosphorylated RalA.
We then used these phospho-specific antibodies to de-
termine whether Ser183 and Ser194 in RalA were targets
of PP2A Ab. In cells lacking the expression of Ab, a condi-
tion where we previously found evidence for increased
RalA activity, these antibodies recognized higher levels
of phosphorylated RalA, compared to cells expressing
Ab. To verify the specificity of these antibodies, we treated
RalA immune complexes with calf intestinal phosphatase
Figure 5. Ab-Mediated RalA Dephosphorylation Regulates RalA Activity
(A) Phosphorylation status of RalA in cells expressing or lacking Ab. Total serine phosphorylated proteins were isolated from HEK TER cells express-
ing shGFP or shAb by immunoprecipitation with a phospho-serine antibody. Immunoblot analysis was performed using anti-RalA antibodies. WCL,
whole cell lysate.
(B) Interaction between Ab and RalA mutants. FLAG-tagged Ab and HA-tagged RalA (wild-type wt, S11A, S183A, S194A) were expressed in 293T
cells. Ab-specific complexes were isolated using anti-Flag agarose followed by immunoblotting using FLAG or RalA specific antibodies.
(C) Detection of RalA phosphorylation at Ser183 and Ser194. Control vector (vector), WT RalA and S11A, S183A, S194A and S183/194A RalA mutants
were overexpressed in HEK TERV and HEK TER-shAb cells and HA-immune complexes isolated. Immunoblotting was performed sera form mice
immunized with phospho-Ser183 RalA and phospho-Ser194 RalA peptides (IMS), XL13 hybridoma supernatant, or FLAG (M2) antibodies.
(D) Phospho-RalA expression levels were analyzed in the membrane fraction of lung carcinoma cell lines (H1437, H2009, H1450 and H838). Immu-
noblotting was performed XL13 hybridoma supernatant or FLAG (M2) antibodies (total RalA).
(E) Activity of RalA alanine substitution mutants. Amount of GTP-bound RalA was determined in HEK TER-shAbshRalA cells expressing shRNA-
resistant forms of RalA.
(F) AI growth and tumor formation of HEK TER-shAb-shRalA cells expressing shRalA-resistant RalA alanine substitution mutants. shRalA-resistant
forms of WT RalA and RalA mutants were expressed in HEK TER-shAbshRalA cells. The number of AI colonies formed is presented as the
mean ± SD for three independent experiments. Tumors are reported as number of tumors formed per number of injection sites.(CIP), which eliminated the RalA species detected by
these phosphospecific antibodies without affecting total
RalA levels (Figures S8A–S8C). Moreover, when we over-
expressed WT RalA and S183A, S194A and S183/194A
RalA mutants in HEK TER cells lacking Ab expression(HEK TER-shAb), we found that the S183A and S194A
RalA mutants showed decreased levels of phospho-
RalA compared to WT RalA. Importantly, we failed to
detect phosphorylated RalA in cells expressing the double
S183/194A RalA mutant with these phosphospecificCell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc. 977
antibodies (Figure 5C). These observations confirmed that
Ser183 and Ser184 in RalA are the targets of PP2A Ab-
containing complexes.
We then analyzed phospho-RalA levels in lung cancer
cell lines harboring Ab mutations. Phosphorylated forms
of RalA were undetectable in the H1437 and H2009 cell
lines that harbor WT Ab. In contrast, we found that RalA
was phosphorylated in H838 and H1450 cell lines that
lack functional Ab alleles (Figure 5D). Together, these
studies strongly implicated Ser183 and Ser194 in RalA
as substrates of PP2A complexes containing Ab.
To determine whether the phosphorylation state of RalA
contributes to transformation induced by loss of Ab func-
tion, we created S183A and S194A RalA mutants resistant
to the RalA-specific shRNA by introducing silent substitu-
tions into the RalA coding sequence (Figure S8D). We
overexpressed these shRNA-resistant RalA mutants in
HEK TER cells in which both RalA and Ab were sup-
pressed (HEK TER-shAb-shRalA). The overexpression of
WT RalA or the S11A RalA mutant restored RalA activity
while expression of the S194A or S183A RalA mutants
was unable to complement the suppression of endoge-
nous RalA (Figure 5E). These observations suggest that
PP2A Ab-mediated dephosphorylation of RalA at Ser183
and Ser194 down-regulates its activity. Consistent with
these observations, suppression of RalA in HEK TER-
shAb cells inhibited AI growth and tumor formation, and
expression of a shRalA-resistant form of WT RalA or the
S11A RalA mutant restored the tumorigenic phenotype
caused by Ab suppression (Figure 5F). In contrast, overex-
pression of shRalA-resistant S183A or S194A RalA
mutants failed to reverse the transforming phenotype
induced by loss of Ab expression. Together, these obser-
vations implicate the control of phosphorylation of RalA at
Ser183 and Ser194 by PP2A Ab as a critical regulatory
step in RalA function.
DISCUSSION
PP2A Aa and Ab: Distinct Tumor
Suppressor Complexes
Several PP2A complexes have been implicated in cancer
development (reviewed in Schonthal, 2001). The observa-
tion that mutations of the PP2A Ab structural subunit occur
in many human tumors suggested that this subunit partic-
ipates in malignant transformation. Here we show that Ab
loss-of-function cooperates with the expression of LT,
hTERT andH-RAS to convert human cells to a transformed
phenotype. Moreover, that the introduction of a WT Ab
allele into lung cancer cell lines carrying loss-of-function
Ab mutations partially reversed the tumorigenic pheno-
type of these cells. These findings, together with prior
observations in human tumor specimens (Zhou et al.,
2003), implicate PP2A Ab as a tumor suppressor gene.
Somatic mutations of the PP2A structural Aa subunit
have also been reported in human cancers (Calin et al.,
2000; Ruediger et al., 2001b). Although these distinct
PP2A A isoforms, a and b, are 86% identical (Hendrix978 Cell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc.et al., 1993), it remained unclear whether these two
isoforms are functionally interchangeable (Gotz et al.,
2000). We previously showed that near complete suppres-
sion of PP2A Aa subunit expression induced cell death by
apoptosis while cancer-associated PP2A Aa mutations
contributed to human cell transformation by creating
a state of haploinsufficiency (Chen et al., 2005). In con-
trast, loss-of-function of both Ab alleles leads to human
cell transformation. These observations are consistent
with prior studies, which showed that mutations of the
Aa gene occur on one allele while alterations of the Ab
gene are found in both alleles (Wang et al., 1998). Here
we also found that the Aa isoform cannot functionally
substitute for Ab. Consistent with prior observations, we
also found that only the Aa isoform interacts SV40 ST,
suggesting that the transformed phenotype induced by
suppression of Ab occurs by distinct mechanism from
that induced by expression of ST. Collectively, these ob-
servations indicate that PP2A complexes containing Aa
or Ab are functionally distinct and contribute to cell trans-
formation by discrete mechanisms (Figure 6).
PP2A Ab Binds and Regulates the Small
GTPase RalA
Here we show that PP2A Ab interacts with and modulates
the activity of the small GTPase RalA. RalA is a multifunc-
tional protein, regulating membrane transport, apoptosis,
transcription, cell migration and cell proliferation [reviewed
in (Camonis and White, 2005; Feig, 2003)]. RalA activation
results in activation of several signaling pathways, includ-
ing the activation of phospholipase D1 and Src kinase (Goi
et al., 2000; Jiang et al., 1995), vesicle transport (Moska-
lenko et al., 2002), filopodia formation (Ohta et al., 1999),
epidermal growth factor-induced cell motility (Gildea
et al., 2002) and AI growth (Chien and White, 2003; Lim
et al., 2005; Panner et al., 2006). The activation of known
RalA effector proteins such as RalBP1 or the exocyst has
not previously been directly linked to tumorigenesis. How-
ever, other signaling molecules regulated by RalA, such as
phospholipase D1, Src, JNK, NF-kB and cyclin D, may
contribute to cancer progression (Feig, 2003; Lim et al.,
2005).
Consistent with prior reports, we observed that RalA
suppression diminished the ability of transformed cells
to form AI colonies (Chien and White, 2003; Lim et al.,
2005). Strikingly, RalA depletion in cells lacking Ab
completely abolishes AI growth, indicating that RalA is
necessary for transformation induced by suppression of
Ab. Furthermore, we found that cancer-derived Ab
mutants fail to form complexes with RalA protein. Since
Ab mutations occur throughout its coding sequence, we
speculate that these cancer-associated mutations fail to
bind RalA due to disruption of functional heterotrimeric
PP2A Ab complexes rather than through specific interac-
tions with these mutant residues. This model is consistent
with recent structural determinations of the PP2A Aa com-
plex (Cho and Xu, 2007; Xu et al., 2006). Functionally,
these Ab mutants thus fail to down-regulate RalA resulting
Figure 6. Distinct Mechanisms Used by
PP2A Aa and Ab Subunit Mutants in
Transformation
Cancer-associated PP2A Aa mutations result
in Aa haploinsufficiency, which induces human
cell transformation by selectively eliminating
PP2A B56g containing complexes. One conse-
quence is constitutive AKT phosphorylation. In
contrast, PP2A Ab loss-of-function permits the
accumulation of activated RalA.in the increased RalA activity observed in cells lacking
functional Ab complexes.
We also found accumulation of RalA phosphorylated at
Ser183/Ser194 in cells lacking Ab expression, suggesting
that RalA activity can be modulated by (de)phosphoryla-
tion. Prior studies have identified two pathways to activate
RalA. The cycling of RalA between GDP and GTP bound
forms is regulated by guanine nucleotide exchange
factors (GEFs), which promote GTP binding, and GTPase
activating proteins, which promote GTP hydrolysis (Feig,
2003; Quilliam et al., 2002). At least four RalGEFs are
known which are stimulated by activated RAS. Moreover,
several GAPs down-regulate RalA (Emkey et al., 1991). In
addition, the elevation of intracellular Ca2+ levels and inter-
action of RalA with calmodulin also enhances the binding
of GTP to RalA in vitro [reviewed in (Feig, 2003; van Dam
and Robinson, 2006)]. Together, these observations iden-
tify phosphorylation of RalA as another mechanism that
regulates RalA activity and cell transformation.
A prior report demonstrated that the phosphorylation of
the RAS family members Rap1a and Rap1b proteins
occurs at C-terminal residues Ser180 or Ser179, respec-
tively. This change in phosphorylation modulates the abil-
ity of Rap1a to associate and regulate its downstream
targets (Altschuler and Lapetina, 1993; Hu et al., 1999;
Quilliam et al., 1991). RalA has also been shown to be
phosphorylated at Ser194 by Aurora kinase A (Wu et al.,
2005). Here we have identified two additional RalA phos-
phorylation sites - Ser11 and Ser183. Using alanine
substitution Ab mutants, we identified S183 and S194 as
residues dephosphoryalted by PP2A Ab and required for
the interaction of RalA and PP2A Ab. Although PP2A Ab
is likely to have other substrates in addition to RalA, the
regulation of RalA phosphorylation appears to play a criti-
cal role in transformation associated with loss of functional
Ab in human cancers. In agreement with these findings,
overexpression of Aurora A kinase was shown to increase
the amount of GTP-bound RalA, thereby promoting colla-
gen I-induced migration and AI growth in MDCK cells (Wu
et al., 2005). Thus, the phosphorylation of RalA at Ser183
and Ser194 may represent a RAS-independent mecha-nism of RalA regulation; however, further studies are
required to identify the kinase(s) that are responsible for
RalA phosphorylation at these sites.
PP2A Ab, RalA, and Human Cell Transformation
Several recent studies implicate the activation of RalA in
cell transformation. In HEK cells expressing LT, ST and
hTERT, substitution of an oncogenic allele of H-RAS
with a Ras effector mutant that binds selectively to
RalGEFs (RAS V12, G37) led to AI growth. However, in
these experiments, the additional expression of Ras
mutants that bind either Raf (RAS V12, S35) or PI3K
(RAS V12, C40) was necessary to achieve tumorigenicity
(Hamad et al., 2002; Rangarajan et al., 2004), indicating
that the activation of RalGEFs contributes to but does
not suffice to substitute for RAS. Furthermore, overex-
pression of constitutively-activated forms of RalA (G23V
or Q72L) induces AI growth of immortalized HEK cells
and human fibroblasts expressing LT, ST and hTERT
(Lim et al., 2005). These observations implicate the activa-
tion of RalGEFs as an important Ras effector pathway in
human cells.
Here we demonstrate that suppression of PP2A Ab
leads to RalA activation, which substitutes for ST expres-
sion to induce both AI growth and tumorigenicity in human
cells expressing LT, hTERT and H-RAS. Together with our
prior observations that implicated PI3K signaling as a
target of B56g suppression or ST expression (Chen
et al., 2004; Zhao et al., 2003), these findings confirm
that the pathways activated by ST and H-RAS are highly
overlapping. Consistent with these observations, consti-
tutively active forms of RalA cooperate with H-RAS or
Raf to induce cell transformation (Urano et al., 1996).
Indeed, we and others have found that expression of
a degradation resistant form of c-Myc (Yeh et al., 2004)
or expression of an activated allele of PI3K (Zhao et al.,
2003) also substitute for ST in human cell transformation.
Further studies are necessary to determine whether these
effector pathways induce particular transformation phe-
notypes that are not adequately assessed in standard
in vitro transformation assays or whether the activationCell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc. 979
of multiple RAS effector pathways is necessary to bypass
regulatory feedback loops normally induced by physiolog-
ical Ras signaling.
Although the specific targets of RalA critical for cell
transformation are not yet known, elevated levels of
GTP-bound RalA have been reported in pancreatic cancer
cell lines (Lim et al., 2005, 2006), and we found that lung
cancer cell lines lacking functional PP2A Ab exhibit
elevated levels of activated RalA. Thus, the activation of
RalA may represent one critical downstream effector of
RAS signaling, one that is regulated by the antagonistic
actions of proto-oncogenes such as RAS and tumor
suppressor genes such as PP2A Ab.
These observations establish PP2A Ab as a serine thre-
onine phosphatase tumor suppressor gene that contrib-
utes to cell transformation by regulating the phosphoryla-
tion status and activity of RalA. Moreover, since PP2A
complexes composed of PP2A Aa and Ab regulate differ-
ent signaling pathways, these observations challenge the
view that phosphatases act promiscuously and constitu-
tively. Instead these findings suggest that phosphatases
such as PP2A regulate specific phosphorylation events
necessary for the initiation and/or maintenance of tumors.
Thus, elucidating the role of PP2A and other phospha-
tases in these processes is likely to provide further insights
into cell transformation and identify additional cancer
targets.
EXPERIMENTAL PROCEDURES
Protein Phosphatase Activity
The protein phosphatase activity in immune complexes was deter-
mined as described (Chen et al., 2004). For measuring phosphatase
activity in whole cell lysates, and free phosphate was first removed
from cell lysates by passage through a Sephadex G-25 column (Amer-
sham, Piscataway, NJ). Serine/threonine phosphatase activity in these
cell lysates was then measured by the capacity to dephosphorylate
a synthetic phosphothreonine peptide RRA(pT)VA specific for PP2A.
Specificity was confirmed using purified PP2A core enzyme in the
presence or absence of 5 nM OA. After 30 min incubation at RT, free
phosphate was measured colorimetrically.
Proliferation, AI Growth, and Tumor Formation
13104 cells were plated in triplicate and counted every 4 d. For popu-
lation doublings, a seeding density of 13104 cells in a 10-cm plate was
used for all cultures. Soft agar and tumorigenicity assays were per-
formed as described (Hahn et al., 1999). AI colonies were counted
4 wk after seeding at 103magnification. The number of tumors formed
was determined 40 d after injection.
RalA Activation Assay
The RalA activation assay was performed using RalA activation kit
(Upstate Biotechnology, Lake Placid, NY). Cell lysates (2 mg) were pre-
cleared with glutathione agarose (Amersham Biosciences, Piscat-
away, NJ) and then incubated with 20 ml of RalBP1 agarose for 1 hr.
The beads were washed, and the samples were subjected to 12%
SDS-PAGE, transferred to nitrocellulose membranes and immunoblot-
ted with an anti-RalA antibody (BD Biosciences, San Jose, CA).
Generation of Phosphospecific RalA Antibodies
To generate phosphospecific antibodies, 6 mice were immunized with
two KLH-conjugated phospho-peptides (phospho-Ser183 and phos-980 Cell 129, 969–982, June 1, 2007 ª2007 Elsevier Inc.pho-Ser194). After 3 immunizations, murine sera from 5 mice were
tested by immunoblotting KLH-conjugated phosphorylated RalA
peptides. Hybridomas were generated from one of these mice; 1000
supernatants were tested by ELISA; and the 13 positive supernatants
were then analyzed by immunoblotting RalA phospho-peptides. We
used the sera from the positive immunized mice and the supernatant
from one positive parental line, XL13.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and eight figures and can be found with
this article online at http://www.cell.com/cgi/content/full/129/5/969/
DC1/.
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